Health news and discussion on TalkFuse.
Ebola: Why is there still no vaccine?
The current Ebola outbreak in the Democratic Republic of Congo is caused by the Bundibugyo strain, for which there is no licensed vaccine or approved treatment. Researchers say this gap reflects missed opportunities to prepare after earlier outbreaks, alongside limited funding and decisions to prioritise other threats.
The existing Ervebo vaccine is licensed for the Zaire strain, not Bundibugyo or Sudan. A German research team has studied whether Ervebo can prompt immune responses to other Ebola types, raising hopes of broader protection, though vaccine effectiveness can only be confirmed during an outbreak. Bundibugyo may be less aggressive than Zaire, but infected people can remain mobile longer and spread it without realising.
In short
- The current outbreak involves a strain without a licensed vaccine.
- Ervebo was developed for the Zaire strain.
- Researchers are investigating whether it could protect against other strains.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The lack of a licensed Bundibugyo vaccine reflects a failure to prepare for a known but less frequent threat, despite earlier outbreaks offering opportunities to develop and test protection. Investing in vaccines for multiple Ebola strains could save lives and limit spread, especially because people with Bundibugyo may remain mobile while infectious; relying on a vaccine for another strain leaves protection uncertain.
The case against
Vaccine research and stockpiling require limited public health funds, so decision-makers have had to weigh Bundibugyo against other threats with greater frequency or expected harm. Since Ervebo is designed for the Zaire strain and broader protection remains unconfirmed, prioritising a Bundibugyo vaccine could divert resources from interventions with established benefits, while still leaving uncertainty about effectiveness.
Explained simply
Ebola is a group of related viruses that can cause severe illness. The viruses have different strains, including Zaire, Bundibugyo and Sudan, and protection against one strain does not necessarily protect against another.
Ervebo is a licensed vaccine for the Zaire strain, which caused major outbreaks in West Africa and the Democratic Republic of Congo. It is not licensed for Bundibugyo or Sudan, and there is no approved vaccine or treatment specifically for Bundibugyo.
Preparing vaccines for less common strains requires research and funding before outbreaks happen. Scientists can study immune responses in the laboratory, but whether a vaccine prevents illness must be established in people during an outbreak, when cases are available to assess.